64625
Methyl cellulose
medium viscosity, Methoxyl content 27.5-31.5 %
Synonym(s):
Methyl cellulose
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
CAS Number:
MDL number:
UNSPSC Code:
12352201
PubChem Substance ID:
NACRES:
NA.21
Recommended Products
Quality Level
form
powder
composition
Methoxyl content, 27.5-31.5%
color
white to off-white
viscosity
1200-1800 mPa.s, 2 % in H2O(20 °C)
SMILES string
[*]OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO[*])O[C@@H](O[*])[C@H](O[*])[C@H]2O[*])[C@H](O[*])[C@@H](O[*])[C@@H]1O[*]
InChI key
YLGXILFCIXHCMC-JHGZEJCSSA-N
Looking for similar products? Visit Product Comparison Guide
Other Notes
To gain a comprehensive understanding of our extensive range of Polysaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Timothy M OʼShea et al.
Nature communications, 11(1), 6203-6203 (2020-12-06)
Biomaterials hold promise for therapeutic applications in the central nervous system (CNS). Little is known about molecular factors that determine CNS foreign body responses (FBRs) in vivo, or about how such responses influence biomaterial function. Here, we probed these factors
Matthew J Caicco et al.
Journal of controlled release : official journal of the Controlled Release Society, 166(3), 197-202 (2013-01-12)
Stimulation of endogenous neural stem/progenitor cells (NSPCs) with therapeutic factors holds potential for the treatment of stroke. Cyclosporin A (CsA) is a particularly promising candidate molecule because it has been shown to act as a survival factor for these cells
Eyal Zur
International journal of pharmaceutical compounding, 17(1), 10-22 (2013-05-01)
Compounding pharmacists throughout the world are compounding a special type of capsule called "slow-release." This type of capsule is a compounding pharmacy application of the commercial hydrophilic matrix tablets. It is a relatively simple system that allows formulating a robust
Navnit Shah et al.
Journal of pharmaceutical sciences, 102(3), 967-981 (2013-01-03)
The present work deals with improving the solubility of vemurafenib, a practically insoluble drug, by converting it into an amorphous-solid dispersion using a solvent-controlled precipitation process. The dispersion containing vemurafenib and hypromellose acetate succinate (HPMCAS), an enteric polymer, is termed
Min-Soo Kim et al.
International journal of pharmaceutics, 445(1-2), 108-116 (2013-02-12)
The purpose of this study was to develop supersaturatable formulations for the enhanced solubility and oral absorption of sirolimus. Supersaturatable formulations of hydrophilic polymers and/or surfactants were screened by formulation screening, which is based on solvent casting. The solid dispersion
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service